Patient engagement has become a new buzz word in drug development. Nevertheless, much uncertainty still exists among stakeholders on how and when to best engage patients in the product development and approval processes. Join us as we explore the role of patients in the drug development process, discuss the challenges to incorporating patient preferences, and explain the implications of these challenges on all stakeholders involved.
During this webinar you will:
- Learn about ways stakeholders can partner with patient communities to obtain input on important factors to consider during product development.
- Learn about FDA’s PFDD initiative and the meetings held to date.
- Obtain stakeholders’ opinions on the initiative so far.
Other Speakers Include:
Marc M. Boutin, Executive Vice President and Chief Operating Officer, National Health Council
Pat Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD)
Theresa M. Mullin, Ph.D., Director, Office of Strategic Programs, U.S. Food and Drug Administration
Eleanor Perfetto, Ph.D., Professor of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy